Merck, Eisai sign deal to further develop, sell Eisai cancer drug

(Reuters) – Merck & Co Inc and Japan’s Eisai Co Ltd on Wednesday announced a potential multibillion-dollar collaboration to develop and sell Eisai’s cancer drug Lenvima, which is already approved in dozens of countries for two uses.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply